SeaStar Medical to Present at Noble Capital Markets’ NobleCon20 on December 4, 2024
26 nov. 2024 08h00 HE
|
SeaStar Medical Holding Corporation
DENVER, Nov. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering
22 nov. 2024 09h15 HE
|
Autonomix Medical, Inc.
THE WOODLANDS, TX, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted...
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical’s Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares
22 nov. 2024 08h30 HE
|
SeaStar Medical Holding Corporation
SeaStar Medical urges stockholders to vote FOR all proxy proposals prior to the Special Meeting of Stockholders to be held November 26, 2024 DENVER, Nov. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar...
Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
11 nov. 2024 08h00 HE
|
Autonomix Medical, Inc.
Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder group went to zero opioid use at 4-6...
Record Monthly Enrollment Achieved in SeaStar Medical’s Pivotal Adult AKI Trial
01 nov. 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, Nov. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE
31 oct. 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
Positive Preliminary Results Demonstrate Autonomix’s Proprietary RF Ablation Technology’s Ability to Reduce Opioid Use in Ongoing Human Clinical Trial
28 oct. 2024 08h00 HE
|
Autonomix Medical, Inc.
100% of the responder group went to zero opioid use at 4-6 weeks post-procedure Up to 75% of late-stage pancreatic cancer patients are prescribed opioids and data suggests 20% are at risk for abuse...
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update
25 oct. 2024 11h32 HE
|
SeaStar Medical Holding Corporation
Data illustrate the potential of QUELIMMUNE™️ with cost neutrality starting at 6 days of therapy and a significant reduction in total hospitalization costs in children with acute kidney injury ...
Autonomix Medical, Inc. to Participate in a Virtual Investor “What This Means” Segment on Wednesday, October 30th
25 oct. 2024 11h30 HE
|
Autonomix Medical, Inc.
THE WOODLANDS, TX, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted...
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024
25 oct. 2024 08h30 HE
|
SeaStar Medical Holding Corporation
Data illustrate the potential of QUELIMMUNE™️ with cost neutrality starting at 6 days of therapy and a significant reduction in total hospitalization costs in children with acute kidney injury ...